Hologic Inc HOLX
We take great care to ensure that the data presented and summarized in this overview for HOLOGIC INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOLX
View all-
Vanguard Group Inc Valley Forge, PA26.2MShares$1.95 Billion0.03% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD24.1MShares$1.79 Billion0.99% of portfolio
-
Black Rock Inc. New York, NY23.1MShares$1.72 Billion0.04% of portfolio
-
Manufacturers Life Insurance Company, The Toronto, A611MShares$819 Million0.68% of portfolio
-
State Street Corp Boston, MA10.1MShares$750 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA8.34MShares$620 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA5.83MShares$433 Million0.03% of portfolio
-
Victory Capital Management Inc5.5MShares$409 Million0.25% of portfolio
-
Black Creek Investment Management Inc. Toronto, A64.03MShares$299 Million12.85% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.71MShares$276 Million0.04% of portfolio
Latest Institutional Activity in HOLX
Top Purchases
Top Sells
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at HOLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2025
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
83,589
+5.96%
|
-
|
|
Nov 04
2025
|
Karleen Marie Oberton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,095
+12.54%
|
-
|
|
Nov 04
2025
|
Jan Verstreken Group President, International |
BUY
Grant, award, or other acquisition
|
Direct |
15,196
+11.32%
|
-
|
|
Nov 04
2025
|
Essex D Mitchell Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,116
+19.57%
|
-
|
|
Nov 04
2025
|
Mark W. Horvath President, Breast & Skeletal |
BUY
Grant, award, or other acquisition
|
Direct |
2,278
+19.05%
|
-
|
|
Nov 04
2025
|
Benjamin Jordan Cohn Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,656
+15.68%
|
-
|
|
Oct 20
2025
|
Christiana Stamoulis Director |
SELL
Open market or private sale
|
Direct |
7,402
-13.52%
|
$540,346
$73.07 P/Share
|
|
Oct 20
2025
|
Christiana Stamoulis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,402
+11.91%
|
$266,472
$36.04 P/Share
|
|
Sep 22
2025
|
Stephen P Macmillan Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
138,358
-3.46%
|
$9,131,628
$66.83 P/Share
|
|
Sep 22
2025
|
Stephen P Macmillan Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,358
+9.15%
|
$5,395,962
$39.96 P/Share
|
|
May 30
2025
|
Brandon Schnittker Div. President, GYN Surgical |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-1.12%
|
$4,278
$62.17 P/Share
|
|
May 07
2025
|
Martin D Madaus Director |
BUY
Open market or private purchase
|
Indirect |
5,445
+50.0%
|
$299,475
$55.24 P/Share
|
|
Apr 07
2025
|
Wayde D. Mc Millan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,742
+50.0%
|
-
|
|
Feb 26
2025
|
Christiana Stamoulis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+3.79%
|
-
|
|
Feb 26
2025
|
Stacey D. Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+26.51%
|
-
|
|
Feb 26
2025
|
Amy Mc Bride Wendell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+7.62%
|
-
|
|
Feb 26
2025
|
Martin D Madaus Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+45.8%
|
-
|
|
Feb 26
2025
|
Nanaz Mohtashami Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+30.84%
|
-
|
|
Feb 26
2025
|
Ludwig Hantson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+12.58%
|
-
|
|
Feb 26
2025
|
Charles J Dockendorff Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,864
+35.17%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 146K shares |
|---|---|
| Exercise of conversion of derivative security | 169K shares |
| Open market or private purchase | 5.45K shares |
| Payment of exercise price or tax liability | 12.6K shares |
|---|---|
| Open market or private sale | 171K shares |